Stem cell technologies are now entering a third decade in the biomedical spotlight, with the potential for an accelerated therapeutic impact in the next few years. As often is the case, ocular disorders present some of the best opportunities to test and refine this latest advance in therapeutics. What’s the potential for stem cell applications in the eye? This month we review the basics of stem cell biology, explore potential applications in the front of the eye and describe some recent progress. We conclude with a discussion of how this cutting-edge technology can move from an experimental protocol to an everyday therapy.
Stem cell research dates back to the early 20th century, but it wasn’t until 1981 that embryonic stem cells were grown successfully in culture from mice; human cultured hESCs were first described in 1998.
At its core the principle of stem cell therapy is simple: Replace a tissue or organ that is failing with the means to rebuild itself. The eye is uniquely suited for this type of therapeutic approach, as demonstrated by the long-standing success of corneal transplants. In addition to the physical accessibility of ocular structures, corneal transplant benefits from the immune privilege that reduces the risks of rejection present with other organ transplant methods. Cadaver cornea transplant isn’t appropriate for all corneal pathologies, however, and there are always patients for whom transplants simply don’t succeed, but the clinical experience that we have gained from decades of allogeneic therapies has jump-started research into stem cell-based approaches to corneal disease.
A normal cornea has its own supply of stem cells in the limbal epithelial stem cells. Localized to specialized niches at the corneal-scleral junction (the palisades of Vogt)
Limbal cell defects can result from either inherited or acquired conditions, and they can be partial or complete. Rare genetic disorders such as aniridia or dyskeratosis congenita are associated with LSCD, but it is more commonly the result of a trauma such as chemical exposure, fire, repeated ocular surgery involving the limbus or adverse responses to contact lens use. Diagnosis is made by clinical presentation and impression cytology.
The first step in managing LSCD is assessment and optimization of the health of the ocular surface. Surface debridement may be required, and artificial tears and topical corticosteroids may also be needed. In cases of partial and asymptomatic LSCD, this approach along with examinations may be all that is needed.
Ex vivo expansion of limbal cell grafts can improve outcomes in cases of limbal stem cell deficiency. Limbal stem cell transplant is the second most common form of stem cell-based therapy; only bone marrow transplantation is more common.11 Stem cells can be harvested from the fellow eye and transplanted directly into the diseased eye in a procedure known as conjunctival limbal autograft. This approach is useful for cases of unilateral LSCD where the non-diseased eye has a healthy stem cell population. However, care must be taken not to induce LSCD in the donor eye.
If the patient is not a candidate for autologous transplantation due to conditions such as bilateral LSCD, other transplant therapies may be used. A living, related donor can provide donor limbal cells or they can be harvested from otherwise healthy cadaver corneas. Both of these techniques require topical and systemic immunosuppression, and both have had only modest long-term (beyond two years) success.
Patients with the most severe ocular surface disease (such as those with Stevens-Johnson syndrome) seem to have better outcomes with another approach: the combined conjunctival and keratolimbal allograft. In this procedure the patient receives tissue from a living related donor and a cadaver. This approach is useful for patients with severe ocular scarring; Stevens-Johnson patients in particular don’t respond well to traditional corneal cadaver transplants.
In order to avoid the risks of immune rejection associated with allografts as well as the need for lifelong immunosuppression therapy, ex vivo expansion of autologous cells has been carried out and remains the only clinically validated stem cell-based therapy that is routinely performed in ophthalmology.
Cultured limbal epithelial transplantation is a two-step process in which a small graft is harvested from the donor eye and then expanded in the laboratory using a tissue matrix to increase the number of progenitor corneal cells.
If autologous limbal stem cells are not available, as is the case with total LSC deficiency, another source of stem cells must be found. Alternative cell sources being investigated include: oral mucosa; hair-follicle stem cells; mesenchymal stem cells (e.g., umbilical cord lining stem cells, dental pulp stem cells and adipose tissue-derived stem cells); and embryonic stem cells.
Cultivated oral mucosal epithelial transplantation uses autologous cells obtained from the inferior buccal mucosa. Short-term results have been positive, but long-term efficacy has yet to be assessed.
Human embryonic stem cells are derived from the inner cell mass of a 3- to 5-day-old embryo. Embryonic stem cells are more robust than adult somatic stem cells and they have a theoretically unlimited capacity to divide, and are by definition pluripotent: They can differentiate into all cell and tissue types given the correct sequence of differentiating stimuli. The establishment of hESC lines, as well as the ability to obtain single-cell biopsies without harming embryos has eliminated some of the religious and ethical concerns that surrounded earlier stem cell research.
The task of promoting appropriate differentiation has been addressed by growing hESCs on a collagen matrix using a nutrient broth similar to what is found in vivo in the limbal stem cell niche. When these cells are transplanted onto human corneas in vitro, they behave according to the normal corneal epithelial developmental process, forming corneal epithelial-like cells.
While these studies provide useful insights into how hESCs may be used for corneal disease, the use of embryonic cells may eventually give way to cells derived from the reprogramming or inducing of non-embryonic stem cells into becoming pluripotent, undifferentiated stem cells. Induced pluripotent stem cells are adult somatic stem cells that have been reprogramed to return to an embryonic state, and so would provide tissue necessary for allografts of any tissue type.
The reprogramming has been possible using combinations of transcription factor cocktails; most of these mixes include transcription factors Oct4 and Sox2 in combination with several other factors. Somatic cells engineered to express these mixes regress to an undifferentiated state; stable expression maintains this iPSC state, which can then be directed toward a new path of differentiation. Several reports have described a method that successfully produced corneal epithelial cells from iPSCs.
Although researchers have demonstrated that reprogramming somatic cells to pluripotency is possible, significant challenges remain. Some of the factors used to induce the iPSC state are associated with oncogenic transformation (such as c-Myc), and the risk of teratoma formation needs to be evaluated. The ability of iPSC to differentiate into cells that are able to work in concert with existing cells also needs to be determined.
The use of animal products in cell culturing, such as mouse feeder cells and fetal calf serum, is another area of concern. The risks of xeno-contamination and zoonotic disease transmission are unknown, so animal-product-free systems are being explored. Similar efforts are being applied to the ex vivo expansion techniques described earlier. To circumvent these issues, one study employed autologous limbal stem cells grown in the patient’s own serum on an FDA-approved contact lens instead of using mouse feeder cells and human amniotic membranes. Early results are promising.
The clinical experience with corneal transplants and the availability of donor tissue have given anterior segment stem cell research a sizeable head start on posterior segment efforts, but a strong focus on stem cell therapies for congenital retinal diseases and on conditions such as dry AMD will soon level the playing field. As an example, a Phase I/II study of hESC therapy for macular degeneration was recently published, with promising safety and graft survival data providing an encouraging outlook for the future.
Finally, it’s important to recognize that, like all new therapeutic strategies, the viability of these promising technologies depends upon the ability to refine the techniques to the point where they can be economically viable. Efforts to address this issue are focusing on the technologies required to create a consistent supply of high- quality iPSCs that are safe and respond to reprogramming in a reliable, predictable way.
Dr. Abelson is a clinical professor of ophthalmology at Harvard Medical School. Dr. McLaughlin is a medical writer at Ora Inc.